2024
Hepatitis B Virus Status and Clinical Outcomes in IgA Nephropathy
Gao M, Xu L, Li Y, Wang X, Chen P, Shi S, Liu L, Lv J, Hong F, Zhang H, Zhou X. Hepatitis B Virus Status and Clinical Outcomes in IgA Nephropathy. Kidney International Reports 2024, 9: 1057-1066. PMID: 38765575, PMCID: PMC11101714, DOI: 10.1016/j.ekir.2024.01.009.Peer-Reviewed Original ResearchChronic HBV infectionHBV infectionIndependent risk factorIgAN progressionRisk factorsIgA nephropathyIgAN patientsMultivariable cause-specific hazards modelHepatitis B virus infectionHepatitis B virus statusPropensity Score Matching AnalysisConcurrent HBV infectionB virus infectionKidney disease progressionAnti-HBV therapyGlomerular filtration rateCause-specific hazards modelProgression of IgANSignificant risk factorsHepatitis B antigenHBV therapyRenal outcomesClinical outcomesFiltration rateVirus status
2022
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Collaborators G, Sheena B, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, Abbastabar H, Abdoli A, Ali H, Adane M, Adegboye O, Adnani Q, Advani S, Afzal M, Afzal S, Meybodi M, Ahadinezhad B, Ahinkorah B, Ahmad S, Ahmad T, Ahmadi S, Ahmed H, Ahmed M, Rashid T, Akalu G, Aklilu A, Akram T, Al Hamad H, Alahdab F, Alem A, Alem D, Alhalaiqa F, Alhassan R, Ali L, Ali M, Alimohamadi Y, Alipour V, Alkhayyat M, Almustanyir S, Al-Raddadi R, Altawalah H, Amini S, Amu H, Ancuceanu R, Andrei C, Andrei T, Anoushiravani A, Ansar A, Anyasodor A, Arabloo J, Arab-Zozani M, Argaw A, Argaw Z, Arshad M, Artamonov A, Ashraf T, Atlaw D, Ausloos F, Ausloos M, Azadnajafabad S, Azangou-Khyavy M, Jafari A, Azarian G, Bagheri S, Bahadory S, Baig A, Banach M, Barati N, Barrow A, Batiha A, Ramirez D, Belgaumi U, Berhie A, Bhagat D, Bhardwaj N, Bhardwaj P, Bhattacharyya K, Bhojaraja V, Bijani A, Biondi A, Bodicha B, Bojia H, Boloor A, Bosetti C, Braithwaite D, Briko N, Butt Z, Cámera L, Chakinala R, Chakraborty P, Charan J, Chen S, Choi J, Choudhari S, Chowdhury F, Chu D, Chung S, Cortesi P, Cowie B, Culbreth G, Dadras O, Dai X, Dandona L, Dandona R, De la Hoz F, Debela S, Dedefo M, Demeke F, Demie T, Demissie G, Molla M, Desta A, Dhamnetiya D, Dhimal M, Dhimal M, Didehdar M, Doan L, Dorostkar F, Drake T, Eghbalian F, Ekholuenetale M, Sayed I, Zaki M, Elhadi M, Elmonem M, Elsharkawy A, Enany S, Enyew D, Erkhembayar R, Eskandarieh S, Esmaeilzadeh F, Ezzikouri S, Farrokhpour H, Fetensa G, Fischer F, Foroutan M, Gad M, Gaidhane A, Gaidhane S, Galles N, Gallus S, Gebremeskel T, Gebreyohannes E, Ghadiri K, Ghaffari K, Ghafourifard M, Ghamari S, Ghashghaee A, Gholami A, Gholizadeh A, Gilani A, Goel A, Golechha M, Goleij P, Golinelli D, Gorini G, Goshu Y, Griswold M, Gubari M, Gupta B, Gupta S, Gupta V, Gupta V, Haddadi R, Halwani R, Hamid S, Hamidi S, Hanif A, Haque S, Harapan H, Hargono A, Hariri S, Hasaballah A, Hasan S, Hassanipour S, Hassankhani H, Hay S, Hayat K, Heidari G, Herteliu C, Heyi D, Hezam K, Holla R, Hosseini M, Hosseini M, Hosseinzadeh M, Hostiuc M, Househ M, Huang J, Hussein N, Iavicoli I, Ibitoye S, Ilesanmi O, Ilic I, Ilic M, Irham L, Islam J, Ismail N, Jacobsen K, Jadidi-Niaragh F, Mamaghani A, Jayaram S, Jayawardena R, Jebai R, Jha R, Joseph N, Joukar F, Kaambwa B, Kabir A, Kabir Z, Kalhor R, Kandel H, Kanko T, Kantar R, Karaye I, Kassa B, Bohan P, Keykhaei M, Khader Y, Khajuria H, Khan G, Khan I, Khan J, Khan M, Khanali J, Khater A, Khatib M, Khodadost M, Khoja A, Khosravizadeh O, Khubchandani J, Kim G, Kim H, Kim M, Kim Y, Kocarnik J, Kolahi A, Koteeswaran R, Kumar G, La Vecchia C, Lal D, Landires I, Lasrado S, Lazarus J, Ledda C, Lee D, Lee S, Lee Y, Levi M, Li J, Lim S, Lobo S, Lopukhov P, Loureiro J, MacLachlan J, Razek H, Razek M, Majeed A, Makki A, Malekpour M, Malekzadeh R, Malik A, Mansour-Ghanaei F, Mansournia M, Martins-Melo F, Matthews P, Mendoza W, Menezes R, Meretoja T, Mersha A, Mestrovic T, Miller T, Minh L, Mirica A, Mirmoeeni S, Mirrakhimov E, Misra S, Mithra P, Moazen B, Mohamadkhani A, Mohammadi M, Mohammed S, Moka N, Mokdad A, Moludi J, Momtazmanesh S, Monasta L, Moradi G, Moradzadeh M, Moradzadeh R, Moraga P, Mostafavi E, Mubarik S, Muniyandi M, Murray C, Naghavi M, Naimzada M, Swamy S, Natto Z, Nayak B, Nazari J, Negoi I, Negru S, Nejadghaderi S, Kandel S, Nguyen H, Ngwa C, Niazi R, Nnaji C, Noubiap J, Nowroozi A, Nuñez-Samudio V, Oancea B, Ochir C, Odukoya O, Oh I, Olagunju A, Olakunde B, Bali A, Omer E, Otstavnov S, Oumer B, Padubidri J, Pana A, Pandey A, Park E, Kan F, Patel U, Paudel U, Petcu I, Piracha Z, Pollok R, Postma M, Pourshams A, Poustchi H, Rabiee M, Rabiee N, Rafiei A, Rafiei S, Raghuram P, Rahman M, Rahmani A, Rahmawaty S, Rajesh A, Ranasinghe P, Rao C, Rao S, Rashidi M, Rashidi M, Rawaf D, Rawaf S, Rawassizadeh R, Rezaei N, Rezapour A, Rezazadeh-Khadem S, Rodriguez J, Rwegerera G, Sabour S, Saddik B, Saeb M, Saeed U, Sahebkar A, Saif-Ur-Rahman K, Salahi S, Salimzadeh H, Sampath C, Samy A, Sanabria J, Sanmarchi F, Santric-Milicevic M, Sarveazad A, Sathian B, Sawhney M, Seidu A, Sepanlou S, Seylani A, Shahabi S, Shaikh M, Shaker E, Shakhmardanov M, Shannawaz M, Shenoy S, Shetty J, Shetty P, Shibuya K, Shin J, Shobeiri P, Sibhat M, Singh A, Singh J, Singh S, Skryabin V, Skryabina A, Sohrabpour A, Song S, Tabaeian S, Tadesse E, Taheri M, Tampa M, Tan K, Tavakoli A, Tbakhi A, Tefera B, Tehrani-Banihashemi A, Tesfaw H, Thapar R, Thavamani A, Tohidast S, Tollosa D, Tosti M, Tovani-Palone M, Traini E, Tran M, Trihandini I, Tusa B, Ullah I, Vacante M, Tahbaz S, Valdez P, Varthya S, Vo B, Waheed Y, Weldesenbet A, Woldemariam M, Xu S, Jabbari S, Yaseri M, Yeshaw Y, Yiğit V, Yirdaw B, Yonemoto N, Yu C, Yunusa I, Zahir M, Zaki L, Zamani M, Zamanian M, Zastrozhin M, Vos T, Ward J, Dirac M. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology 2022, 7: 796-829. PMID: 35738290, PMCID: PMC9349325, DOI: 10.1016/s2468-1253(22)00124-8.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsAll-age prevalencePrevalence of chronic HBV infectionChronic HBV infectionMortality-to-incidence ratioGlobal burdenNational prevalence of hepatitis B virusGlobal Burden of Disease StudyHepatitis B virusBurden of Disease StudyGlobal Burden of DiseaseHBV-related diseasesSpatiotemporal Gaussian process regressionVital registration systemsMortality due to cirrhosisRisk Factors StudyDeath rateAcute hepatitis B.Health Sector StrategyIncidence of liver cancerBurden of diseaseHBV infectionGlobal Health Sector StrategyWHO Member StatesHBV interventions
2021
Hepatitis B Awareness Campaign in Chinese Americans: A Community Outreach Model to Facilitate Screening and Linkage to Care
Hyun C, Wang H, Ko O, Lee S, McMenamin J. Hepatitis B Awareness Campaign in Chinese Americans: A Community Outreach Model to Facilitate Screening and Linkage to Care. International Journal Of Health Promotion And Education 2021, 59: 366-377. DOI: 10.1080/14635240.2021.1964375.Peer-Reviewed Original ResearchHepatitis B virusAccessing CareChronic hepatitis BChinese AmericansLinkage-to-careChinese-American adultsCommunity outreach modelChinese-AmericansPrevalence of chronic HBV infectionHepatitis B virus-infected individualsScreening educationHepatitis B virus prevalenceHepatitis B surface antigenChronic HBV infectionAwareness of infectionAdequate careOutreach modelPatient awarenessB surface antigenLiver-related morbidityInadequate educationCareSeropositive subjectsHBV infectionHepatitis B
2020
Prevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.Peer-Reviewed Original ResearchConceptsChronic hepatitis B virus infectionHepatitis B virus infectionB virus infectionWorld Health OrganizationChronic HBVVirus infectionMajor global health problemChronic HBV infectionGlobal health problemHBV prevalenceHBV infectionHBV screeningLiver cirrhosisSubstantial morbidityLiver diseaseClinical complicationsHepatocellular carcinomaHealth problemsElimination planPrevalenceDisease FoundationHealth OrganizationInfectionPeer-reviewed literatureUnited StatesA phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).
Harding J, Abou-Alfa G, Shi Y, Whang-Peng J, Yuen M, Saif W, Tian A, Gu S, Lam W, Liu S, Cheng Y, Chu E, Yen Y. A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2020, 38: tps601-tps601. DOI: 10.1200/jco.2020.38.4_suppl.tps601.Peer-Reviewed Original ResearchProgression-free survivalHepatocellular carcinomaPrimary endpointControl armFirst-line systemic treatment optionMedian progression-free survivalTreatment-related adverse eventsCTCAE version 4.0Prior systemic therapyChronic HBV infectionDisease control rateECOG performance statusObjective response ratePlacebo-controlled studySystemic treatment optionsPhase 2 studyRate of gradeKey eligibility criteriaAdvanced hepatocellular carcinomaPotential clinical benefitTyrosine kinase inhibitorsActivation/proliferationQuality of lifeTraditional Chinese medicineAdvanced disease
2017
Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Digestive Diseases And Sciences 2017, 63: 61-71. PMID: 29177849, DOI: 10.1007/s10620-017-4850-1.Peer-Reviewed Original ResearchConceptsCommunity oncology clinicsCommunity teaching hospitalHBV screening rateOncology clinicTeaching hospitalHBV infectionScreening ratesCancer chemotherapyUniversity HospitalChronic hepatitis B virus infectionHepatitis B virus infectionHepatitis B Virus ScreeningHBV reactivation riskChronic HBV infectionB virus infectionHBV core antibodyHBV surface antigenAdult cancer patientsRisk of reactivationHospital networkLarge university hospitalCore antibodyHBV exposureHBV screeningBackgroundCancer patientsRisk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal Of The American Academy Of Dermatology 2017, 77: 88-97.e5. PMID: 28495497, DOI: 10.1016/j.jaad.2017.01.037.Peer-Reviewed Original ResearchConceptsChronic HBV infectionBiologic therapyHBV infectionViral reactivationAntiviral prophylaxisCore antibodyHCV infectionHepatitis BSafety of biologic therapiesHistory of viral hepatitisSystematic reviewIsolated core antibodyHBV core antibodyLow-risk patientsRetrospective cohort study designRetrospective cohort studyReactivated HBV infectionCohort study designPsoriasis patientsViral hepatitisEvaluate safetyFollow-upCohort studyPrimary outcomeTreatment duration
2015
Are current screening protocols for chronic hepatitis B virus infection adequate?
Mortensen E, Kamali A, Schirmer PL, Lucero-Obusan C, Winston CA, Oda G, Winters MA, Durfee J, Martinello RA, Davey VJ, Holodniy M. Are current screening protocols for chronic hepatitis B virus infection adequate? Diagnostic Microbiology And Infectious Disease 2015, 85: 159-167. PMID: 27009896, DOI: 10.1016/j.diagmicrobio.2015.12.005.Peer-Reviewed Original ResearchConceptsOccult HBV infectionHBV infectionHBV DNAOBI prevalenceChronic hepatitis B virus infectionHepatitis B virus infectionEnzyme immunoassayHBsAg-negative patientsInitiation of immunosuppressionLook-back investigationChronic HBV infectionSerum HBV DNAB virus infectionHBV DNA testingCurrent screening protocolsPatient blood samplesHBsAg enzyme immunoassayHBV testingOBI rateCohort patientsHBsAg testingAntigen testingHBV screeningInfection screeningHBV core
2010
Liver histology and HBV DNA levels in chronically HBV infected patients with persistently normal alanine aminotransferase.
Montazeri G, Rahban M, Mohamadnejad M, Zamani F, Hooshyar A, Fazlolahi A, Abedian S, Ghoujeghi F, Estakhri A, Montazeri F, Razjoyan H, Mamarabadi M, Alimohamadi M, Tavangar SM, Malekzadeh R. Liver histology and HBV DNA levels in chronically HBV infected patients with persistently normal alanine aminotransferase. Archives Of Iranian Medicine 2010, 13: 193-202. PMID: 20433223.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlanine TransaminaseAnalysis of VarianceBiopsy, NeedleCohort StudiesDNA, ViralFollow-Up StudiesHepatitis B e AntigensHepatitis B virusHepatitis B, ChronicHumansImmunohistochemistryLinear ModelsLiver Function TestsMaleMiddle AgedMonitoring, PhysiologicMultivariate AnalysisReference ValuesRetrospective StudiesRisk AssessmentROC CurveSensitivity and SpecificitySeverity of Illness IndexTime FactorsConceptsBaseline HBV DNAChronic HBV infectionHBV DNA levelsHBeAg-negative chronic HBV infectionNegative chronic HBV infectionNormal alanine aminotransferase levelsNormal alanine aminotransferaseAlanine aminotransferase levelsHBV DNAHBV infectionTotal scoreAminotransferase levelsHistological activityAlanine aminotransferaseMedian levelsMedian baseline HBV DNADNA levelsAssociation of histologySecond liver biopsyActive liver diseaseMedian time intervalAdjusted odds ratioLog10 IULiver histologyLiver biopsy
2009
Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications
Gupta S, Altice FL. Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications. Journal Of Urban Health 2009, 86: 263-279. PMID: 19184447, PMCID: PMC2648882, DOI: 10.1007/s11524-008-9338-z.BooksConceptsChronic viral infectionsHepatitis B virus infectionB virus infectionReview of diagnosisHBV infectionViral infectionVirus infectionMedical careChronic HBV infectionChronic hepatitis BChronic medical conditionsComprehensive medical carePublic health burdenPublic health impactHigh-risk behaviorsPublic health implicationsProvision of vaccinationUS correctional facilitiesCorrectional settingsHBV vaccineHepatitis BViral hepatitisTreatment guidelinesChronic infectionChronic illness
2007
Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm
Yood M, Quesenberry CP, Guo D, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Caldwell C, Manos MM. Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm. Journal Of Viral Hepatitis 2007, 15: 28-36. PMID: 18088242, DOI: 10.1111/j.1365-2893.2007.00893.x.Peer-Reviewed Original ResearchConceptsChronic HBV infectionHepatitis B virusIncidence of HCCHBV infectionHepatocellular carcinomaComparison patientsPositive hepatitis B surface antigen testEvidence of HBVHepatitis B surface antigen testChronic hepatitis B virusGeneral population comparison cohortHepatitis B virus infectionChronic HBV patientsPopulation comparison cohortB virus infectionUS health systemHBV patientsComparison cohortAntigen testB virusHCC riskVirus infectionStringent criteriaHBV diagnosisPatientsIncidence of non‐Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection
Yood M, Quesenberry CP, Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM. Incidence of non‐Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007, 46: 107-112. PMID: 17526021, DOI: 10.1002/hep.21642.Peer-Reviewed Original ResearchConceptsChronic HBV infectionChronic hepatitis B virus infectionHepatitis B virus infectionPopulation-based tumor registryB virus infectionHuman immunodeficiency virusIncidence of NHLHBV infectionVirus infectionChronic HBVComparison patientsHodgkin's lymphomaHepatitis C virus infectionCox proportional hazards modelHistory of NHLC virus infectionCharlson Comorbidity IndexCases of NHLProportional hazards modelUnited States health systemState health systemInfection cohortComorbidity indexHCV infectionComparison cohort
2005
Adherence to hepatitis B virus vaccination at syringe exchange sites
Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. Journal Of Urban Health 2005, 82: 151-161. PMID: 15746385, PMCID: PMC3456633, DOI: 10.1093/jurban/jti016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionConnecticutDiagnostic Tests, RoutineFemaleHepatitis BHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHumansImmunization ProgramsMaleMiddle AgedMobile Health UnitsNeedle-Exchange ProgramsPatient ComplianceSubstance Abuse, IntravenousUrban Health ServicesConceptsInjection drug usersHepatitis B virusHBV infectionHealth care servicesHigh riskCare servicesHepatitis B virus (HBV) vaccinationActive injection drug usersPreventive health care servicesB virus vaccinationVaccine-eligible patientsChronic HBV infectionHepatitis C virusSyringe exchange programsSyringe exchange sitesMobile health care servicesDaily injectorsHBV vaccinationVaccination seriesVirus vaccinationC virusB virusPreventive vaccinationVaccinationDrug users
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply